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Authors year age	   study	  span follow-­‐up treatment tumour	  grade PSA number tumour	  region
Gannon	  et	  al,	  CTR 2009 63.4	  ±	  4.7 1991-­‐2001 up	  to	  5	  years	  (mean	  99.8	  months) RP / 11.4	  ±	  9.2 40 cancer	  core
Gannon	  et	  al,	  ADT 2009 62.1	  ±	  5.1 1991-­‐2001 up	  to	  5	  years	  (mean	  99.8	  months) ADT / 12.4	  ±	  11.2 35 cancer	  core
Alev	  et	  al, 2015 61.6±	  6.2(range	  46-­‐72) 2000-­‐2011 71.4(range	  11-­‐105)months RP T	  2/3-­‐23/77 9.9±	  8.7(range	  2.8-­‐55) 100 cancer	  core
Lanciotti	  et	  al, 2014 67(45-­‐75) 2000-­‐2011 50.4	  months RP T2/3a/3b/4-­‐33/35/23/2 7.6(1.01-­‐86.8) 93 hot	  spots
Nonomura	  et	  al, 2010 71(50-­‐88) 1999-­‐2002 54.5(2.7-­‐181.5) ADT T1/2/3/T4-­‐9/21/29/11 50.1(5.2-­‐5820) 71 cancer	  core
Gollapudi	  et	  al,West	  LA 2013 62.8 1991-­‐2003 / RP / 10.2 332 cancer	  core
Gollapudi	  et	  al,	  Durham 2013 622.2 1993-­‐2004 / RP / 10.4 205 cancer	  core
Shimura	  et	  al, 2000 63.1(45.2-­‐77.9) / 46.6(0.8-­‐131.7) RP T1/2/3-­‐7/61/13 / 81
total/stroma/c
ancer/hot	  spot
Lissbrant	  et	  al, 2000 73(52-­‐95) 1975-­‐1983 RP / 85 hot	  spots
Hu	  et	  al, 2015
Non-­‐metastasis-­‐73.00±7.76	  
Metastasis-­‐70.05±10.05 2008-­‐2009 up	  to	  5	  years	  (mean	  99.8	  months) RP T1-­‐2/3-­‐4-­‐18/24
Non-­‐metastasis-­‐
16.33±7.15	  Metastasis-­‐
87.29±48.12 42 cancer	  core
Yang	  et	  al, 2004 63(45-­‐77) 1983-­‐1996 47.75(0.8-­‐131.7)months RP T1/2/3a-­‐21/44/13 15(0.7-­‐100) 78
total/stroma/c
ancer
Takayama	  et	  al, 2008 70(50-­‐88) 1997-­‐2000 46.8(2.0-­‐96.0) RP/Rad T1/2/3/T4-­‐24/55/53/3 19.9(4.3-­‐5820) 135 total
